GSK plc announced on January 28, 2025, that the European Medicines Agency has accepted for review its application for depemokimab, a new asthma treatment, which shows promise for reducing exacerbation rates and hospitalizations. If approved, this will be the first ultra-long-acting biologic requiring only two doses per year.